SMAD3 and metabolic dysfunction-associated steatohepatitis: 2.2. Although the pSmad3L Pathway in Hepatocytes Tended to Predominate While the pSmad3C Pathway Became Quiescent during Chronic Liver Disease Progression in both HCV and NASH, Smad3 Phospho-Isoforms in NASH Livers Varied more Widely than in HCV-Infected Livers at All Fibrotic Stages